TGFβ-IN-3
TGFβ-IN-3 (Compound 8) is a long-acting tumor-activating prodrug of TGFβR1 inhibitor. TGFβ-IN-3 can achieve selective drug release in tumors, and the tumor/blood ratio is increased by 2.2 times. TGFβ-IN-3 can be used for the study of colon cancer[1].
Product Specifications
CAS Number
2857845-34-0
UNSPSC
12352005
Target
TGF-β Receptor
Related Pathways
TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
OC(CCCCCCCCCCCCCCCCC(N[C@H](C(O)=O)CCC(NCCOCCOCC(NCCOCCOCC(N[C@@H](CC(C)C)C(N[C@@H](CO)C(NCC(N[C@@H](CCCCN)C(NC(C=C1)=CC=C1COC(NCOCCN2C(C3=NN4C(C=C3)=NC=C4C#N)=C(C5=CC(Cl)=C(C=C5)F)N=C2)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Molecular Formula
C79H114ClFN16O20
Molecular Weight
1662.30
References & Citations
[1]Zhang Y, et al. Long-Acting Tumor-Activated Prodrug of a TGFβR Inhibitor. J Med Chem. 2021 Nov 11;64 (21) :15787-15798.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15344613 1 Vial
Lentiviral human FASN shRNA (UAS) - Lentiviral human FASN shRNA (UAS) (100)
Sign In for Pricing
View Details 